We observed decreased tumor cell proliferation in the lungs of gefitinib-treated mice challenged with DARPP-32-silenced HCC287GR cells (Fig. 7c), confirming that DARPP-32 knockdown enhances EGFR TKI-induced anti-cancer effects in gefitinib-resistant tumors in vivo. Here, PPP1R1B is linked to neoplasm.